Factors associated with the appearance of subclinical atherosclerosis in systemic lupus erythematosus
Keywords:
subclinical atherosclerosis, systemic lupus erythematosus, risk factorAbstract
Introduction: Systemic lupus erythematosus is an inflammatory, chronic, multisystemic disease, which is defined by its multiple clinical features and by the almost invariable presence of autoantibodies directed against one or more components of the cell nucleus.
Objective: To characterize patients with Systemic Lupus Erythematosus and to identify its possible relationship with subclinical atherosclerosis.
Methods: A descriptive cross-sectional study of patients diagnosed with Systemic Lupus Erythematosus, treated at the Rheumatology Center in Havana, was carried out during the period from October 2015 to October 2017. The sample was non-probabilistic and consisted of 50 patients. Descriptive and inferential statistics were used.
Results: Of the total number of patients, 54.0% (n=27) had subclinical atherosclerosis. The traditional risk factors that showed association with the presence of plaque in patients with SLE were hypercholesterolemia, 70.4% (n=19) and hypertriglyceridemia 55.6% (n=15). A relationship was observed between the time of evolution, the presence of accumulated damage, renal compromise, CRP figures and accumulated dose of steroids, with the presence of subclinical atherosclerosis.
Conclusions: A higher average age was found in patients with SLE and presence of plaque. The traditional risk factors that showed association with the presence of atherosclerotic plaque were hypercholesterolemia and hypertriglyceridemia. An association was found between the time of evolution, the presence of accumulated damage, renal compromise, CRP figures and the accumulated dose of steroids, with the presence of plaque. In the study patients, the use of chloroquine was associated with the absence of subclinical atherosclerosis.
Downloads
References
Battagliotti CA, Kilstein J, Gentiletti AA, Pons Estel B. Lupus Eritematoso Sistémico. Aspectos clínicos y terapéuticos. 2da. ed. Buenos Aires: Ed: CB Eitores; 1998. p. 187-94.
Petri M. La cohorte de Lupus de Hopkins. Puesta al día. Clínic Rheumatic Disease of North America (Edición Española). 2000;(2):203-17.
Font J. Khamashta M, Vilardell M. Lupus Eritematoso Sistémico. Segunda parte, Capítulo VI. Barcelona: Ed. MRA, S.L; 1996. p. 73-239.
Hetjmancik MR, Wright IJC, Quint R, Jennings, FL. The cardiovascular manifestations of systemic lupus erythematosus. Am Heart J. 1964;68(1):119-30.
Rahman P, Urowitz MB, Gladman DD, Bruce IN, Genest J. Contribution of tradicional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol [Internet]. 1999 [citado 15 May 2017];26(11):2363-8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/10555892/
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation [Internet] 2005 [citado 15 May 2017];112(17):2735-52. Disponible en: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.105.169404
Cistermas M. Ateroesclerosis en Enfermedades Reumatológicas. ¿Mito o Realidad?. Reumatología [Internet]. 2006 [citado 15 May 2017];22(1):9-13. Disponible en: https://pesquisa.bvsalud.org/portal/resource/pt/lil-452444
Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum [Internet]. 2001 [citado 3 May 2017]; 2001(10):2331-7. Disponible en: https://pubmed.ncbi.nlm.nih.gov/11665973/
Liang MH, Socher SA, Roberts WN, Esdaile JM. Measurements of systemic lupus erythematosus activity in clinical research. Arthritis Rheum [Internet]. 1988 [citado 3 May 2017];31(7):817-25. Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.1780310701
Hernández Muñiz Y, Guibert Toledano ZM, Reyes Llerena GA. Correlación de las cifras de proteína C reactiva y aterosclerosis en pacientes con lupus eritematoso sistémico. Rev Cuba Reumatol [Internet]. 2015 Ago [citado 3 May 2017];17(2):[aprox. 5 p.]. Disponible en: http://www.revreumatologia.sld.cu/index.php/reumatologia/article/view/414/pdf_18
Tan EM, Cohen AS, Fries JF, Masi AT, Mcshane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum [Internet]. 1982 [citado 3 May 2017];25(11):1271-7. Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.1780251101
Doria A, Shoenfield Y, Wu R, Gambari PF, Puato M, Ghirardello A, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis [Internet]. 2003 [citado 3 May 2017];62(11):1071-7. Disponible en: https://pubmed.ncbi.nlm.nih.gov/14583570/
Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jansen-McWilliams, et al. Age-specific Incidente Rates of Myocardial Infarction and Angina in Women with Systemic Lupus Erythematosus: Comparison with the Framingham Study. Am J Epidemiol [Internet]. 1997 [citado 3 May 2018];145(5):408-15. Disponible en: https://academic.oup.com/aje/article-abstract/145/5/408/120887
Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg I. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet [Internet]. 1996 [citado 3 May 2018];348(9035):1120-4. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0140673696030322
Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol [Internet]. 1995 [citado 3 May 2018];22(7):1259-64.Disponible en: https://europepmc.org/article/med/7562755
Guibert Toledano ZM, Reyes Llerena GA, Hernández Muñiz Y, Ugarte Moreno D, Miñoso Arafi Y. Morbilidad cardiovascular y evaluación de aterosclerosis en pacientes con lupus eritematoso sistémico. Rev Cuba Reumatol [Internet]. 2016 Ago [citado 3 May 2018];18(2):[aprox. 7 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1817-59962016000200002&lng=es
Estévez del Toro M, Chico Capote A, Barahona Jorge RA, Jiménez Paneque R, Hernández Castro J. Prevalencia de enfermedad vascular aterosclerótica en pacientes cubanos con lupus eritematoso sistémico. Reumatol Clin [Internet]. 2008 [citado 3 May 2018];4(1):13-8. Disponible en: https://www.sciencedirect.com/science/article/pii/S1699258X0871790X
Duarte C, Couto M, Vaz C, Ines L, Malcata A. Perfil de risco cardiovascular numa população portuguesa de doentes com LES. Acta Reumatol Port [Internet]. 2009 [citado 3 May 2018];34(2):349-57. Disponible en: http://hdl.handle.net/10400.4/630
Rodríguez Hernández R, Alberteris Rodríguez A, López Báster J, Diéguez Martínez M, Miguel-Soca PE, Cutié Anido Y. Factores de riesgo asociados a hipertensión arterial en pacientes con lupus eritematoso sistémico. Holguín, Cuba. Rev Haban Cienc Méd [Internet]. 2017 Dic [citado 3 May 2018];16(6):[aprox. 4 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X2017000600011&lng=es
Lahoz C, Mostaza JM. La aterosclerosis como enfermedad sistémica. Rev Esp Cardiol [Internet]. 2007 [citado 3 May 2018];60(2):184-95. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0300893207750091
Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA [Internet]. 1986 [citado 3 May 2018];256:2823-8. Disponible en: https://jamanetwork.com/journals/jama/article-abstract/363231
Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med. 1971 [citado 3 May 2018];74:1-12. Disponible en: https://www.acpjournals.org/doi/abs/10.7326/0003-4819-74-1-1
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet [Internet]. 2005 [citado 3 May 2018];366:1267-78. Disponible en: https://www.thelancet.com/journals/lancet/article/PIIS0140673605673941/fulltext
Cacciapaglia F, Zardi EM, Coppoloni G, Buzzulini F, Margiotta D, Arcarece L, et al. Stiffness parameters, intima-media thickness and early aterosclerosis in systemic lupus erythematosus patients. Lupus [Internet]. 2009 [citado 3 May 2018];18(3):249-56. Disponible en: https://journals.sagepub.com/doi/abs/10.1177/0961203308097571
Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smytheet HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med [Internet]. 1976 [citado 3 May 2018];60(2):221-5. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/0002934376904319
Rubin LA, Urowitz MB, Gladman DD. Mortality in systemic lupus erythematosus: the bimodal mortality pattern revisited. QJM [Internet]. 1985 [citado 3 May 2018];55(1):87-98. Disponible en: https://academic.oup.com/qjmed/article-abstract/55/1/87/1512652
Bruce IN, Urowitz MB, Gladman DD, Ibañez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: The Toronto Risk Factor Study. Arthritis Rheum [Internet]. 2003 [citado 3 May 2018];48(11):3159-67. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/art.11296
Silvariño R, Inoue Sato E. Factores de riesgo para aterosclerosis en enfermedades autoinmunitarias sistémicas. Rev Med Urug [Internet]. 2008 [citado 3 May 2018];24(2):118-32. Disponible en: http://www.scielo.edu.uy/scielo.php?script=sci_arttext&pid=S1688-03902008000200007
Johansson E, Forsberg K, Johnsson H. Clinical and experimental evaluation of the thromboprophylactic effect of hydroxychloroquine sulfate after total hip replacement. Haemostasis [Internet]. 1981 [citado 3 May 2018];10(2):89-96. Disponible en: https://www.karger.com/Article/Abstract/214391
Prowse C, Pepper D, Dawes J. Prevention of the platelet alphagranule release reaction by membrane-active drugs. Thromb Res [Internet]. 1982 [citado 3 May 2018]; 25(3):219-27. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/0049384882902419
van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Disease modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther [Internet]. 2006 [citado 3 May 2018];8(5):[aprox. 10 p.]. Disponible en: https://arthritis-research.biomedcentral.com/articles/10.1186/ar2045
del Rincón I, O’Leary DH, Haas RW, Escalante A. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum [Internet]. 2004 [citado 3 May 2018];50(12):[aprox. 15 p.]. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/art.20661
Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation [Internet]. 2003 [citado 3 May 2018];107(9):1303-7. Disponible en: https://www.ahajournals.org/doi/abs/10.1161/01.CIR.0000054612.26458.B2
Gladman DD, Urowitz MB. Morbidity in systemic lupus erythematosus. J Rheumatol [Internet]. 1987 [citado 3 May 2018];14(Suppl.13):223-6. Disponible en: https://pubmed.ncbi.nlm.nih.gov/3612650/
Downloads
Published
How to Cite
Issue
Section
License
Warning of rights of author
The authors that publish in this journal agree with the following terms:
The authors conserve the rights of author and concede to the journal the right of the first publication, fulfilling with the license Creative Commons Attribution License that allows to others share the work with recognition of the authorship of their articles, and the initial publication in this journal.
The authors can establish separately additional agreements for the no exclusive distribution of the version of the work published in the journal (for example, situate it in an institutional repository, in a personal blog or publish it partial or totally in a book), with a recognition of their initial publication in this journal.
To be able to send the manuscript or part of him passed three months of published, for his evaluation to other publishers, identifying it or not with the same title; whenever allusion is made to our journale and know it the new publisher.
The publishing committee of the Cuban Journal of Rheumatology authorizes to other publishers, to reproduce the articles published in our magazine, whenever it indicate the origin of the same.
The authors should send a document in Office Word application format through the electronic address of the magazine with a similar format to that we include next:
---------------------------------------------------------------------------------------------------------------------
Statement of authorship and cede of articles for the publication of the scientific work in the Cuban Journal of Rheumatology
Date:
Those who subscribe certify that are the authors of the work:
Of this form communicate the originality of our article clearing that the concepts and knowledges of other authors that have included in the text of the article, have been quoted properly in the bibliography.
We do proof besides that the article in question is original and has not been published, total neither partially, in another journal.
To be approved for his publication in the Cuban Journal of Rheumatology, do secession of the rights of publication to the same one through the method that realizes it usually.
In front of any catchword that exist by the article that send to evaluate, relieve of of the responsibility to the Cuban Journal of Rheumatology holding us responsible with all the difficulties that can berelated by any situation.
We include to continuation the name and the signature of all authors and collaborators of this article.
Name: Signature:
